| Lenscrafters #01006 | |
| 230 Bellevue Way Ne, Bellevue, Washington 98004 | |
| (425) 688-0344 |
| Name | Lenscrafters #01006 |
|---|---|
| Organization Name | Luxottica Of America Inc |
| Location | 230 Bellevue Way Ne, Bellevue, Washington 98004 |
| Type | Eyewear Supplier (Equipment, not the service) |
| Phone | (425) 688-0344 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells - called T cells - and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma.
BSD Medical Corporation (NASDAQ:BSDM) reports that significant and "medical practice changing" clinical study results were the subject of a news briefing at Europe's largest cancer congress, ECCO15 – ESMO34, which is being held September 20 to 24, 2009, in Berlin, Germany.
Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.
American Associates, Ben-Gurion University of the Negev announces that Ben-Gurion University of the Negev and Fox Chase Cancer Center in Philadelphia have received a two-year National Institutes of Health research grant to observe "the role of host encoded microRNAs in the maintenance of the measles virus persistent state."
› Verified 7 days ago
| NPI Number | 1205981388 |
| Organization Name | LUXOTTICA OF AMERICA INC. |
| Doing Business As | LENSCRAFTERS #01006 |
| Type | Eyewear Supplier (Equipment, not the service) |
| Address | 230 Bellevue Way Ne, Bellevue, WA 98004 |
| Phone Number | 425-688-0344 |
News Archive
Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells - called T cells - and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma.
BSD Medical Corporation (NASDAQ:BSDM) reports that significant and "medical practice changing" clinical study results were the subject of a news briefing at Europe's largest cancer congress, ECCO15 – ESMO34, which is being held September 20 to 24, 2009, in Berlin, Germany.
Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.
American Associates, Ben-Gurion University of the Negev announces that Ben-Gurion University of the Negev and Fox Chase Cancer Center in Philadelphia have received a two-year National Institutes of Health research grant to observe "the role of host encoded microRNAs in the maintenance of the measles virus persistent state."
› Verified 7 days ago
News Archive
Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells - called T cells - and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma.
BSD Medical Corporation (NASDAQ:BSDM) reports that significant and "medical practice changing" clinical study results were the subject of a news briefing at Europe's largest cancer congress, ECCO15 – ESMO34, which is being held September 20 to 24, 2009, in Berlin, Germany.
Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.
American Associates, Ben-Gurion University of the Negev announces that Ben-Gurion University of the Negev and Fox Chase Cancer Center in Philadelphia have received a two-year National Institutes of Health research grant to observe "the role of host encoded microRNAs in the maintenance of the measles virus persistent state."
› Verified 7 days ago
Acute Pain Management, Pllc Type: Medicare Supplier Location: 1310 116th Ave Ne, Bellevue, Washington 98004 Phone: (425) 440-3351 | |
Center For Prosthetics Orthotics In Type: Medicare Supplier Location: 1231 116th Ave Ne, Bellevue, Washington 98004 Phone: (425) 454-4276 | |
Overlake Optical Type: Eyewear Supplier (Equipment, not the service) Location: 1300 116th Ave Ne, Bellevue, Washington 98004 Phone: (425) 454-7989 | |
Eyecare Center Llc Type: Medicare Supplier Location: 12310 Ne 8th St, Bellevue, Washington 98005 Phone: (425) 455-0001 | |
Fred Meyer Pharmacy #23 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2041 148th Neave, Bellevue, Washington 98007 Phone: (425) 865-8593 |